PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL "ARMORED" CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION. (12th June 2019)

• Record Type: Journal Article
• Authors: Batlevi, C.L.; Palomba, M.L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; Kane, P.; Hall, M.; Bernal, Y.; Lund, N.; Diamonte, C.; Pineda, J.; Halton, E.; Moskowitz, C.; Younes, A.; Sadelain, M.; Brentjens, R.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 166
• Page End: 167
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.124_2629
• Languages: English
• ISSNs: 0278-0232